Mindstate Design Labs
ActiveClinical-stage AI neuroengineering platform
This company has previously operated under “Kykeon Biotechnologies Inc.”, “Kykeon Biotechnologies”. A rename frequently marks a pivot in positioning or product — useful raw material for variant ideas.
About
We're making every therapeutically valuable emotion available on demand in pharmaceutical form. Our Osmanthus platform is an ensemble of AI models that synthesize the world’s largest datasets of psychoactive pharmacology and phenomenology, quantitatively pinpointing the combination of neurotransmitter receptor activity that underlies various emotional as well as cognitive and perceptual states. Our lead program MSD-001 is designed to be rapid-acting and produce heightened emotional and cognitive flexibility without hallucinations. MSD-001 is currently in human trials, and will be the base ingredient for multiple drug combination "emotions in a bottle" such as empathy, awe, clarity, or beauty.
Founders · 2
Creating new classes of psychoactive therapeutics as Founder/CEO at Mindstate Design Labs. Former biotech VC.
BS in biology & chemistry Florida State University. MS & PhD in biology Harvard, tropical plant ecology. 1981 Society of Fellows U Michigan Ann Arbor. 1981-1998 faculty University Delaware, biology & computer science. 1993-2003 External Faculty of the Santa Fe Institute. 1993-1998 invited researcher ATR (Advanced Telecommunications Research Institute) Human Information Processing Research Labs in Japan. In 1998-present Professor of Biology & Computer Science OU. AAAS Fellow. http://tomray.me/
Related startups
Platform for breakthrough mental health research and treatment
AI-designed Affinity Reagents
